The object of the *Gene Technology Act 2000* is:

‘to protect the health and safety of people, and to protect the environment, by identifying risks posed by or as a result of gene technology, and by managing those risks through regulating certain dealings with genetically modified organisms’
Dear Parliamentary Secretary

In accordance with section 136A of the Gene Technology Act 2000 (the Act), I am pleased to present to you the Quarterly Report of the Operations of the Gene Technology Regulator, covering the period 1 July to 30 September 2011.

During this period one licence for dealings involving intentional release of GMOs and five licences for dealings not involving intentional release of GMOs were issued, while 74 physical containment facilities were certified.

Routine monitoring activities for this quarter exceeded the target rate and no significant risks to either human health or the environment were identified.

The Gene Technology Amendment Regulations 2011 and the Guidelines for the Transport, Storage and Disposal of GMOs both commenced on 1 September 2011.

Yours sincerely

Dr Joe Smith
Gene Technology Regulator
21 November 2011
## CONTENTS

### LETTER OF TRANSMITTAL

### CONTENTS

### ABOUT THIS REPORT
- Gene technology regulatory system
  - 1
- Regulation of genetically modified organisms
  - 1
- Statutory committee operations
  - 1
- Other activities of the Gene Technology Regulator
  - 1

### NATIONAL GENE TECHNOLOGY REGULATORY SYSTEM
- Key achievements during this quarter
  - 4
- Licences and other instruments
  - 4
- Monitoring and Compliance
  - 4
- Working collaboratively with States and Territories
  - 4
- Gene Technology Ministerial Council
  - 4
- State and Territory consultation
  - 4
- Australian Government Agency liaison
  - 5
- Public participation
  - 5

### REGULATION OF GENETICALLY MODIFIED ORGANISMS
- Types of Applications
  - 8
- GMO Register
  - 9
- New licences and other instruments
  - 9
- Processing of applications for Dealings involving Intentional Release licences
  - 9
  - Applications received for Dealings involving Intentional Release licences
    - 11
  - Consultation on applications for Dealings involving Intentional Release licences
    - 11
  - Withdrawn applications and surrendered licences for Dealings involving
    - Intentional Release licences
    - 11
  - Clock stopped on Dealings involving Intentional Release licence applications
    - 12
  - Decisions on applications for Dealings involving Intentional Release licences
    - 12
- Decisions on applications for Dealings Not involving Intentional Release licences
  - 12
- Changes to existing licences and other instruments
  - 13
- Emergency Dealing Determinations
  - 13
- Confidential Commercial Information
  - 14
Monitoring and Compliance 14
  Monitoring and Compliance Strategy 15
  Overview of monitoring and compliance for the reporting period 15
  Monitoring of Dealings involving Intentional Releases 16
  Monitoring of Dealing Not involving Intentional Releases 16
  Monitoring of Physical Containment Facilities 17
Monitoring Findings 17
  Dealings involving Intentional Release 17
  Findings for Dealings involving Intentional Release 18
  Findings for Dealings Not involving Intentional Release 18
  Findings for Physical Containment Facilities 19
Practice Reviews 19
Audits 19
Investigations 20

STATUTORY COMMITTEE OPERATIONS 22
Gene Technology Technical Advisory Committee 22
Gene Technology Ethics and Community Consultative Committee 22

OTHER ACTIVITIES OF THE GENE TECHNOLOGY REGULATOR 24
Commencement of the Gene Technology Amendment Regulations 2011 and the Guidelines for the Transport, Storage and Disposal of GMOs 24
International collaboration and coordination 24
Advice on gene technology regulation 25
National Strategy for Unintended Presence of Unapproved GMOs 25
Guidelines 26
OGTR website usage and statistics 26
Internet contacts and freecall number 27
  OGTR email address and freecall number 27
  Monitoring and compliance email inbox 27
  Statutory Committee email inbox 27
  Application and Licence Management email inbox 28
  Contained Dealings Evaluation Section email inbox 28

GLOSSARY 29
ABOUT THIS REPORT

Sub-section 136A(1) of the *Gene Technology Act 2000* (the Act) requires the Gene Technology Regulator (the Regulator) to prepare and give to the Minister after each quarter a report on the operations of the Regulator during that quarter. Sub-section 136A (2) of the Act requires that the report include information on:

- GMO licences issued during the quarter
- breaches of conditions of a GMO licence that have come to the Regulator’s attention during the quarter
- Emergency Dealing Determinations (EDDs) made by the Minister during the quarter
- any breaches of conditions of an EDD that have come to the Regulator’s attention during the quarter
- auditing and monitoring of dealings with GMOs under the Act by the Regulator or an inspector during the quarter.

Its purpose is to inform the community of our roles and responsibilities and to provide a summary of our achievements over the past quarter.

This report has four key sections.

Gene technology regulatory system
Provides advice on the activities and outcomes achieved in relation to the implementation and management of the national regulatory system during the quarter.

Regulation of genetically modified organisms
Provides details on the regulatory activity undertaken, including information about applications for, and action taken with respect to, GMO licences and other instruments under the Act. It also includes details of monitoring, auditing and compliance activities by the Regulator during this quarter.

Statutory committee operations
Reports on the activities of the two advisory committees established under the Act to assist the Regulator and the Gene Technology Ministerial Council.

Other activities of the Gene Technology Regulator
Describes other activities relating to the statutory functions of the Regulator that support the operations of the gene technology regulatory system.
SECTION 1

NATIONAL GENE TECHNOLOGY REGULATORY SYSTEM
NATIONAL GENE TECHNOLOGY REGULATORY SYSTEM

Key achievements during this quarter
The key achievements of the 1 July to 30 September 2011 quarter were:

Licences and other instruments
- No organisations issued with accreditation.
- One licence issued for Dealings involving the Intentional Release (DIR) of GMOs into the environment.
- Five licences issued for Dealings Not involving the Intentional Release (DNIR) of GMOs into the environment
- 74 physical containment facilities certified
- 53 instruments surrendered
- Variation of 60 certifications, six DIR licences and 20 DNIR licences.

Further information on licences and other instruments is contained in Section 2 of this report.

Monitoring and Compliance
Approximately eight percent of current field trial sites and seven percent of post-harvest field trial sites were subjected to routine monitoring during the quarter. This exceeded the target minimum rate of five percent per quarter.

Further information on monitoring and compliance is contained in Section 2 of this report.

Working collaboratively with States and Territories

Gene Technology Ministerial Council
The Gene Technology Ministerial Council (GTMC) oversees the implementation of the regulatory system and comprises one Minister from the Commonwealth and one Minister from each of the States and Territories. Currently, the GTMC includes Ministers from a range of portfolios including health, agriculture and environment.

State and Territory consultation
The Regulator must consult with State and Territory Governments and appropriate local councils during the evaluation of applications for all DIR licences.

For each application for a DIR licence other than a limited and controlled release, the Regulator is required to seek advice on matters relevant to the preparation of the Risk Assessment and
Risk Management Plan (RARMP), and must also seek comment on the RARMP itself once it is prepared. For each application for a limited and controlled release, the Regulator is required to seek comment on the RARMP.

Further information is contained in Section 2 of this report.

**Australian Government Agency liaison**

The close relationship between the OGTR and other Australian Government authorities and agencies continued during this quarter.

Under the Act, the Regulator must seek advice from the Australian Government Environment Minister, and prescribed Australian Government authorities and agencies, on matters relevant to preparing the RARMP for each application for a DIR licence, except those that meet the criteria to be considered as a limited and controlled release.

The prescribed Australian Government authorities and agencies comprise:

- Australian Pesticides and Veterinary Medicines Authority
- Australian Quarantine and Inspection Service
- Food Standards Australia New Zealand
- National Industrial Chemicals Notification and Assessment Scheme
- Therapeutic Goods Administration.

Once a RARMP is prepared for any DIR licence application, the Regulator is required to seek comment on the RARMP from the same prescribed Australian Government authorities and agencies.

In addition, comment is sought on each DIR RARMP from a range of other Australian Government agencies which, while not prescribed in the legislation, have maintained a strong interest in its implementation including the:

- Department of Agriculture, Fisheries and Forestry
- Department of Sustainability, Environment, Water, Population and Communities
- Department of Foreign Affairs and Trade.

During the quarter the Regulator sought advice in respect of one DIR RARMP.

Further information on the processing of DIR applications is contained in Section 2 of this report.

**Public participation**

The Act requires the Regulator to consult the public on the RARMPs for all DIR licence applications. One invitation to the public to comment on a RARMP was issued during the quarter.

Further information on the processing of DIR applications is contained in Section 2 of this report.
SECTION 2

REGULATION OF GENETICALLY MODIFIED ORGANISMS
REGULATION OF GENETICALLY MODIFIED ORGANISMS

Section 2 of the report outlines the regulatory activity undertaken during the quarter. This includes information about applications for GMO licences and other instruments under the Act. This section details any EDDs made pursuant to the Act. It also includes details of monitoring activities and of alleged, admitted or self-reported non-compliances with the Act, or with the conditions imposed by the Regulator on GMO licences or other instruments issued pursuant to the Act. Summary reports on investigations completed during the quarter are supplied. Information on Confidential Commercial Information (CCI) applications has also been provided.

Types of Applications

Under the Act the Regulator is required to make decisions in relation to applications for the following instruments:

- **Dealings involving Intentional Release licences**
  
  DIR licences authorise dealings ranging from limited and controlled releases (e.g. field trials) through to more extensive general or commercial releases of GMOs. DIR licence applications have a statutory timeframe of 255 working days for processing unless the Regulator determines the application is a limited and controlled release application. Then the timeframe for making a decision is 150 working days, or 170 working days if the Regulator determines that the proposed dealings represent a significant risk to human health and the environment.

- **Dealings Not involving Intentional Release licences**
  
  DNIR licences authorise contained dealings with GMOs carried out in laboratories and other containment facilities that are designed to prevent release of the GMO(s) into the environment. These licence applications have a statutory timeframe of 90 working days for making a decision.

- **Accreditations of organisations**
  
  DIR and DNIR licences require organisations which conduct work with GMOs to be accredited. To achieve accreditation, the Regulator must be satisfied that the organisation has, or has access to, a properly constituted and resourced Institutional Biosafety Committee (IBC) and complies with the requirements of the Regulator’s guidelines for accreditation. These applications have a statutory timeframe of 90 working days for making a decision.

- **Certifications of containment facilities**
  
  Certification is required to satisfy the Regulator that a facility which is proposed to be used to conduct dealings with a GMO meets the guideline requirements for the particular level of physical containment specified. These applications have a statutory timeframe of 90 working days for making a decision.
**GMO Register**

The GMO Register is a list of dealings with GMOs that the Regulator is satisfied pose minimal risks to human health and safety and the environment and can therefore be undertaken by anyone, subject to any specified conditions, without the oversight of a licence holder. Under section 78 of the Act the Regulator may determine that dealings with a GMO previously authorised by a licence are to be included on the GMO Register. Such determinations are disallowable instruments.

**New licences and other instruments**

The following table describes the number and type of applications received for new licences and other instruments, as well as the approvals made by the Regulator in the quarter.

<table>
<thead>
<tr>
<th>Application type</th>
<th>Number received</th>
<th>Number approved*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accreditation</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>DIR licence</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>DNIR licence</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Certifications</td>
<td>67</td>
<td>74</td>
</tr>
</tbody>
</table>

* Approvals reported in the current quarter often relate to applications received in previous quarters.

**Processing of applications for Dealings involving Intentional Release licences**

The key steps the Regulator takes when considering an application for a DIR licence are:

- initial screening of the application for completeness
- determining whether or not the application is a limited and controlled release
- considering the applicant’s suitability to hold a licence, having regard to relevant convictions, revocations and suspensions of related licences and permits, and ability to meet conditions of the licence
- seeking comments from prescribed experts, agencies and authorities on issues to consider in the RARMP for all DIR applications except limited and controlled releases
- preparing a consultation RARMP, including proposed licence conditions to manage risks to human health and safety and the environment, and determining whether the proposed dealings may pose a significant risk
• seeking comments on the RARMP from prescribed experts, agencies and authorities and the public

• considering all comments relating to the protection of human health and safety and the environment in finalising the RARMP

• confirming the applicant's suitability, including their capacity to meet licence conditions, and considering policy principles and any relevant policy guidelines.

Once these actions are completed, the Regulator can make a decision on whether or not to grant a licence and the conditions which are to be included in the licence if issued.

The statutory timeframes for making decisions on DIR licences effectively extend over approximately twelve months, and eight or nine months for limited and controlled releases, as they exclude weekends and public holidays observed in the Australian Capital Territory.

This time limit may be extended, that is, the clock may be stopped, if the decision-making process is unable to continue, for example, because of an unresolved application for declaration of CCI or because additional information is sought from the applicant.

The Act and the Gene Technology Regulations 2001 (the Regulations) mandate a minimum 30 day timeframe for each of the one or two rounds of consultation that the Regulator must undertake during the processing of each DIR application. However, consultation periods longer than minimum timeframes are usually allowed to facilitate the provision of information and promote involvement in the decision-making process, particularly by the community. An application for a DIR licence cannot normally be received and decided upon within the same three month reporting period.

The following table shows the progress of applications for DIR licences undergoing evaluation during the quarter.

<table>
<thead>
<tr>
<th>Applications received</th>
<th>Notification of applications*</th>
<th>Consultation on RARMP</th>
<th>Licences issued</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIR 111</td>
<td>DIR 111</td>
<td>DIR 108</td>
<td>DIR 109</td>
</tr>
<tr>
<td>DIR 112</td>
<td>DIR 112</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DIR 113</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Although not required under the Act, all new limited and controlled DIR applications are notified on the OGTR website under ‘What’s New’ and notified to all individuals and organisations on the OGTR mailing list
Applications received for Dealings involving Intentional Release licences
The Regulator received three applications for a DIR licence in the quarter:

- DIR 111—Limited and controlled release of wheat and barley genetically modified for altered grain composition, nutrient utilisation efficiency, disease resistance or stress tolerance—CSIRO
- DIR 112—Limited and controlled release of wheat and barley genetically modified for altered grain composition and enhanced nutrient utilisation efficiency—CSIRO
- DIR 113—Limited and controlled release of cotton genetically modified for insect resistance and herbicide tolerance—Bayer CropScience Pty Ltd.

Consultation on applications for Dealings involving Intentional Release licences
Although not required by the Act, the Regulator issued a ‘Notification of Licence Application’ for two other DIR licence applications. These notifications were posted on the OGTR website and sent to people and organisations on the OGTR mailing list to advise receipt of the applications and indicate when the RARMP is expected to be released for public comment.

- DIR 111—Limited and controlled release of wheat and barley genetically modified for altered grain composition, nutrient utilisation efficiency, disease resistance or stress tolerance—CSIRO
- DIR 112—Limited and controlled release of wheat and barley genetically modified for altered grain composition and enhanced nutrient utilisation efficiency—CSIRO.

There was one invitation to comment on a RARMP issued during the quarter.

- DIR 108—Commercial release of canola genetically modified for herbicide tolerance and a hybrid breeding system (GM InVigor® x Roundup Ready® canola) —Bayer CropScience Pty Ltd.

Full copies of DIR applications can be obtained by contacting the OGTR. Summary information on DIR applications and full consultation RARMPs, including proposed licence conditions, are available via the OGTR website or directly from the OGTR.

Withdrawn applications and surrendered licences for Dealings involving Intentional Release licences
One DIR licence application was withdrawn during the quarter.

- DIR 106—Limited and controlled release of sugarcane genetically modified for production of naturally occurring compounds for use in bioplastics—The University of Queensland

No DIR licences were surrendered during the quarter.
Clock stopped on Dealings involving Intentional Release licence applications

The Regulations determine that a day on which the Regulator is unable to proceed with the decision-making process, or a related function, because information requested from the applicant has not been received, is not counted as part of the prescribed timeframe for making a decision on an application.

One Request for further information on a DIR application was initiated in this quarter:

- DIR 113—Limited and controlled release of cotton genetically modified for insect resistance and herbicide tolerance—Bayer CropScience Pty Ltd.

Decisions on applications for Dealings involving Intentional Release licences

One DIR licence was issued during the quarter:

- DIR 109—Limited and controlled release of banana genetically modified for enhanced nutrition—Queensland University of Technology.

Summary information on DIR applications, finalised RARMPs, licences issued and copies of licences are available from the OGTR website or can be obtained by contacting the OGTR directly.

Decisions on applications for Dealings Not involving Intentional Release licences

These dealings must be conducted in appropriate containment facilities and the dealings must not involve intentional release of a GMO into the environment.

Five DNIR licences were issued during the quarter:

- DNIR 501—A clinical trial assessing the feasibility, safety and efficacy of GM autologous T cells for the treatment of metastatic melanoma—Central Adelaide Local Health Network
- DNIR 503—This study aims to use replication-defective lentiviral vectors to generate GM Schistosoma spp to analyse the function of egg-secreted proteins at different stages of the Schistosoma life cycle—The University of Melbourne
- DNIR 504—This clinical trial aims to test the efficacy and safety of TG1042 for the treatment of nodular basal cell carcinoma—Virax Holdings Limited
- DNIR 505—The purpose of the proposed dealings is to use lentiviral vectors to express HIV genes in mice as a model of HIV infection—The University of Adelaide
- DNIR 506—The purpose of this dealing is to determine whether it is possible to use GM Candida tropicalis to produce industrial quantities of Omega-hydroxyfatty acids—CSIRO.

A full listing of DNIR licences and their current status is available from the OGTR website.
Changes to existing licences and other instruments

The Regulator can, directly or upon application, vary an issued licence or other instrument. Variations involve changes to conditions applied to an instrument or a licence. For example, the Regulator can vary a licence to manage risks if new information or data comes to light. The Regulator must not vary the licence unless he is satisfied that any risks posed by the dealings, proposed to be authorised by the licence as varied, are able to be managed in such a way as to protect the health and safety of people and the environment.

Most variations are made at the request of the instrument/licence holder. Applications for variation to licences have a statutory timeframe of 90 days for making a decision. Additionally, the Regulator can make a decision in relation to an application to transfer a licence/instrument to another person or consent to the surrender of a licence/instrument on request by a licence/instrument holder.

The following table describes the number and type of applications for variation and surrender received in relation to existing licences and other instruments, as well as the number of variations and surrenders approved during the quarter.

<table>
<thead>
<tr>
<th>Type</th>
<th>Number received</th>
<th>Number approved^b</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surrender of accreditations</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Surrender of certification</td>
<td>25</td>
<td>46</td>
</tr>
<tr>
<td>Surrender of DIR licence</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Surrender of DNIR licence</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>Variation of accreditation</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Variation of certification</td>
<td>87</td>
<td>60</td>
</tr>
<tr>
<td>Variation of DIR licence^a</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>Variation of DNIR licence</td>
<td>20</td>
<td>20</td>
</tr>
</tbody>
</table>

^a Includes one variations initiated by the Regulator

^b Numbers reported in this quarter often relate to applications received in previous quarters.

Emergency Dealing Determinations

During this quarter the Regulator did not receive any requests for advice in relation to the making of any Emergency Dealing Determinations (EDD) and no EDDs were in effect.
Confidential Commercial Information

Under section 184 of the Act a person may apply to the Regulator in accordance with section 185 for specified information to be declared confidential commercial information (CCI). Specified information awaiting a decision on an application for CCI is treated as if it were CCI until a decision is made. If the Regulator declares information to be CCI the information is protected from disclosure. More information on the protection of CCI is available on the OGTR website.

During the quarter, the Regulator received two CCI applications in relation to DIR applications. The Regulator made one CCI declaration in relation to a DIR application during the quarter.

Monitoring and Compliance

The aim of OGTR monitoring and compliance activities is to ensure that dealings with GMOs comply with legislative obligations and are consistent with the object of the Act:

‘to protect the health and safety of people, and to protect the environment, by identifying risks posed by or as a result of gene technology, and by managing those risks through regulating certain dealings with GMOs’.

In particular, the Monitoring and Compliance Sections focus on management of dealings at field trial sites and within containment facilities certified by the Regulator to ensure:

- the dissemination of a GMO and its genetic material is restricted
- the persistence of a GMO in the environment is restricted
- the containment of GMOs for dealings not involving intentional release
- effective management of the GMO is maintained.

OGTR monitoring activities comprise the functions of routine monitoring including spot checks, assessment of monitoring findings and, where necessary, recommending corrective action and follow-up activities.

OGTR compliance activities comprise reviews of potential compliance risks, investigations, audits and related enforcement activities.

The Monitoring Section conducts routine monitoring visits of a minimum of 20 percent of field trial sites each year. To achieve this goal a minimum of five percent of current trial sites and five percent of trial sites subject to post-harvest monitoring are monitored each quarter. In addition inspections are conducted on a minimum of 20 percent of PC2 large-scale, PC3 and PC4 facilities per year.
Monitoring and Compliance Strategy

The purpose of routine inspections is to ensure compliance with licence conditions and includes spot checks.

The OGTR strategy for conducting monitoring draws on accumulated operational experience of risk profiling in relation to compliance.

For example, OGTR field trial monitoring coincides, where possible, with periods or circumstances when non-compliance with licence conditions designed to restrict the spread and persistence of the GMOs is more likely to occur (for example, during flowering and harvest of GM crops).

The monitoring program for contained dealings involves inspecting DNIRs and the facilities that those dealings are conducted in. These inspections focus on the integrity of the physical structure of the facility and on the general laboratory practices followed in that facility, including those practices followed for DNIRs and Notifiable Low Risk Dealings (NLRD).

Overview of monitoring and compliance for the reporting period

In addition to routine monitoring visits, compliance with key administrative requirements in licences have been examined.

Total field trial sites monitored: During the quarter, five GM plant field trial sites under DIR licences were subjected to monitoring visits.

- Current field trial sites: Of the 25 sites current in the quarter, two were monitored. This represents a monitoring rate of eight percent of all current sites for the quarter.

- Post-harvest field trial sites: Of the 41 sites subject to post-harvest monitoring in the quarter, three were monitored. This represents a monitoring rate of seven percent of all sites subject to post-harvest monitoring in this quarter.

Monitoring of certified facilities: Monitoring in connection with contained dealings covered four organisations and eight PC facilities. Monitoring of PC facilities encompassed four PC2 laboratories one PC3 laboratory, one PC3 animal facility and two PC2 plant facilities.

Monitoring of contained dealings: During the quarter, the monitoring of the eight PC facilities mentioned above included monitoring for compliance with the general practices that must be followed when undertaking dealings (e.g. DNIRs) that are required to be conducted within contained facilities.

Two DNIRs were monitored during the quarter.
## Monitoring of Dealings involving Intentional Releases

The following table summarises monitoring activities for field trials with GM crop plants for the quarter.

<table>
<thead>
<tr>
<th>Licensed Organisation Name / Location of trial site</th>
<th>Licence Number</th>
<th>No. sites visited</th>
<th>Site status</th>
<th>Crop type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monsanto Australia Limited, New South Wales</td>
<td>DIR 105</td>
<td>1</td>
<td>Current</td>
<td>Canola</td>
</tr>
<tr>
<td>Department of Primary Industries, Victoria</td>
<td>DIR 103</td>
<td>1</td>
<td>Current</td>
<td>Canola</td>
</tr>
<tr>
<td>Bayer CropScience Pty Ltd, Victoria</td>
<td>DIR 069</td>
<td>3</td>
<td>PHM*</td>
<td>Canola</td>
</tr>
</tbody>
</table>

**Total**

3  
5  
Current = 2
PHM* = 3

*PHM = post-harvest monitoring.

## Monitoring of Dealings Not involving Intentional Releases

The following table summaries monitoring activities for DNIRs for the quarter.

<table>
<thead>
<tr>
<th>Licensed Organisation Name</th>
<th>Licence Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austin Health, Victoria</td>
<td>DNIR 104</td>
</tr>
<tr>
<td>BSES Limited, Queensland</td>
<td>DNIR 181</td>
</tr>
</tbody>
</table>

**Total**

2
Monitoring of Physical Containment Facilities

The organisations and the facility types the OGTR visited during the quarter are detailed in the following table.

<table>
<thead>
<tr>
<th>Organisation</th>
<th>Physical Containment (PC) facility</th>
<th>No. facilities visited</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austin Health, Victoria</td>
<td>PC2 laboratory</td>
<td>3</td>
</tr>
<tr>
<td>Children’s Health Service District, Queensland</td>
<td>PC3 laboratory</td>
<td>1</td>
</tr>
<tr>
<td>Queensland Health Forensic and Scientific Services, Queensland</td>
<td>PC3 animal facility</td>
<td>1</td>
</tr>
<tr>
<td>BSES Limited, Queensland</td>
<td>PC2 laboratory</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>PC2 plant facility</td>
<td>2</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>4 facility types</strong></td>
<td><strong>8</strong></td>
</tr>
</tbody>
</table>

Monitoring Findings

Dealing involving Intentional Release

The monitoring findings listed below indicate both the monitoring activities of the OGTR with respect to dealings with GMOs under this Act, in accordance with paragraph 136A(2)(c) of the Act, and the Regulator’s response to those findings.

Findings by inspectors of inconsistencies between an event or state of affairs and the requirements imposed by licence or certification conditions are called non-compliances in this report. However, non-compliances are not regarded as breaches of licence conditions unless proven to be so after investigation. Non-compliances with licence conditions are assessed against a number of considerations before determining the OGTR response. The following aspects of the findings are taken into account as relevant:

- the extent of risk to the health and safety of people and the environment
- the severity of the issue or event involved in the finding
- the culpability of the licence holder or other relevant persons in bringing about the issue or event e.g. whether there was a bona fide mistake involved
- the types of mechanisms available to address the issue or event
- the compliance history of the licence holder or other relevant persons
- mitigating factors such as self-reporting or steps taken voluntarily by the licence holder to address the issue or event
- the need for deterrence.
After having regard to those matters, the OGTR has a range of options including additional investigation to determine if further action is warranted e.g. a recommendation of prosecution for an alleged breach of a licence condition or that a licence be suspended or cancelled. A proven breach of a licence condition will be reported in accordance with paragraph 136A (2) (b) of the Act.

In the case of all matters reported below it was decided that the findings of non-compliances with licence conditions were minor in nature, involved negligible or nil culpability, and could be resolved by reminders, education and/or cooperative compliance.

**Findings for Dealings involving Intentional Release**

There were no non-compliance issues observed for DIRs in the quarter.

**Findings for Dealings Not involving Intentional Release**

There was one non-compliance issue observed for a DNIR that was finalised in the quarter.

<table>
<thead>
<tr>
<th>Organisation</th>
<th>BSES Limited</th>
</tr>
</thead>
<tbody>
<tr>
<td>Licence number and site</td>
<td>DNIR 181</td>
</tr>
<tr>
<td>Summary of dealing</td>
<td>The aim of these dealings is to identify the genes from <em>Leifsonia xyli</em> subspecies involved in the interaction of this fungal pathogen with sugarcane, in order to identify targets for antimicrobial compounds or antibodies.</td>
</tr>
<tr>
<td>Findings</td>
<td>At the time of inspection, the licence holder had not obtained signed statements from staff undertaking dealings indicating that staff had been informed of licence conditions. The licence holder had also failed to record training for staff undertaking dealings, as required by the licence.</td>
</tr>
<tr>
<td>Assessment</td>
<td>No dealings have been conducted under this licence since 2004. Considering the administrative nature of having signed statements in place, the risks to human health and safety and the environment have been assessed as negligible. Also given the training and experience of staff dealing with this licence, failure to maintain training records has been assessed as negligible.</td>
</tr>
<tr>
<td>Compliance management</td>
<td>Given the situation that no work has been conducted since 2004 and currently no staff associated with the licence, BSES Limited expressed its willingness to surrender the licence. Following the inspection, BSES Limited has liaised with OGTR and initiated the surrendering process. However, OGTR reminds BSES Limited that in future, should the organisation wish to seek and hold a DNIR licence, the licence holder and any person covered by it must comply with the applicable conditions of such a licence.</td>
</tr>
</tbody>
</table>
Findings for Physical Containment Facilities

The OGTR’s monitoring of certified PC facilities in the quarter found a small number of non-compliances with certification conditions. All were found to pose negligible risks to human health and safety and the environment.

<table>
<thead>
<tr>
<th>Non-Compliance Issue</th>
<th>Number of PC Facilities inspected</th>
<th>Structure</th>
<th>Equipment</th>
<th>Work practices¹</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>8</td>
<td>3</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

¹ Work practices include personnel training, record keeping, or other actions affecting compliance with certification instruments.

Practice Reviews

The OGTR may initiate Practice Reviews in response to observations made during monitoring activities, or to follow up incident reports that may relate to non-compliance with licence conditions by accredited organisations. Their objective is to determine if licence conditions can be, and are being, effectively implemented.

An accredited organisation may request a Practice Review to assess the effectiveness of systems used by its IBC(s) to ensure that dealings are being conducted in accordance with the Act.

The primary focus of the review process is to determine whether or not practices being used pose potential human health or environmental risks that require management actions to be implemented. In certain instances, where a suspected non-compliance with the Act is identified, the issue may be referred for investigation.

There were no practice reviews completed in the quarter.

Audits

Audits can be initiated by the OGTR or an accredited organisation. An audit can entail:

- documentary evidence
- observations
- assessments of procedures and practices.

These activities are conducted to:

- verify that an accredited organisation has relevant and effective management procedures and practices to meet requirements under the Act, including accreditation requirements, guidelines and any licence conditions applicable to a dealing under the Act
- assess whether or not procedures and practices provide mechanisms to identify and resolve emerging risks
- where appropriate suggest improvements to procedures and practices.
Audits are an opportunity for accredited organisations and the OGTR to share information to improve the risk management of dealings with GMOs under the Act. Audits may focus on a single dealing, a range of dealings (e.g. dealings with a common host organism or dealings within a common climatic zone), the activity of an organisation across a range of dealings, or an activity common to a range of organisations.

There were no audits completed in the quarter.

Investigations
An investigation is an inquiry into a suspected non-compliance with the Act and corresponding state laws with the aim of gathering evidence. Such investigations are not restricted to purely criminal aspects—in the wider context they may include advice on detected flaws and vulnerability in policies, practices and procedures. An investigation may be initiated as a consequence of monitoring by the OGTR, self-reporting by an accredited organisation or by third party reporting.

There were no investigations completed in the quarter.
STATUTORY COMMITTEE OPERATIONS

The Act establishes two committees to provide advice to the Regulator and the Gene Technology Ministerial Council:

- Gene Technology Technical Advisory Committee
- Gene Technology Ethics and Community Consultative Committee.

Gene Technology Technical Advisory Committee

The function of the Gene Technology Technical Advisory Committee (GTTAC) under the Act is to provide scientific and technical advice, on the request of the Regulator or the Ministerial Council, on gene technology, GMOs, GM products, applications made under the Act, the biosafety aspects of gene technology and the need for policy principles, policy guidelines, codes of practice, technical and procedural guidelines in relation to GMOs and GM products and the content of such principles and codes.

During the quarter GTTAC considered the following item out-of-session:

- Consultation RARMP for licence application DNIR 504 (Clinical study of the efficacy and safety of intra-tumoural injection of TG1042 in nodular basal cell carcinoma)

GTTAC did not meet during the quarter.


Gene Technology Ethics and Community Consultative Committee

The function of the Gene Technology Ethics and Community Consultative Committee (GTECCC) under the Act is to provide advice on the request of the Regulator or the GTMC, on a number of matters, including ethical issues relating to gene technology, the need for and content of policy principles, policy guidelines, codes of practice, community consultation in respect of the process for applications for licences covering dealings involving the intentional release of a GMO into the environment, and risk communication matters in relation to those dealings.

GTECCC did not meet during the quarter.

SECTION 4

OTHER ACTIVITIES OF THE GENE TECHNOLOGY REGULATOR
OTHER ACTIVITIES OF THE GENE TECHNOLOGY REGULATOR

Commencement of the Gene Technology Amendment Regulations 2011 and the Guidelines for the Transport, Storage and Disposal of GMOs

The Gene Technology Amendment Regulations 2011 (Amendment Regulations 2011) were made by the Commonwealth Administrator on 2 June 2011 and the Regulator issued new Guidelines for the Transport, Storage and Disposal of GMOs, also on 2 June 2011. Both these instruments commenced on 1 September 2011.

The Amendment Regulations 2011 represents the culmination of a technical review of the Gene Technology Regulations 2001 (the Regulations) initiated by the Regulator in 2008–2009. The amendments include changes to: classification of some GMO dealings as exempt dealings or NLRDs; classification of some GMO dealings involving viral vectors; and the oversight and timeframes of NLRDs. The OGTR provided information to regulated organisations and the public to inform them of the changes.

The new Guidelines for Transport, Storage and Disposal of GMOs consolidate and update previous guidelines covering these activities.

International collaboration and coordination

Under the Act the Regulator’s functions include:

- monitoring international practice in relation to regulation of GMOs
- maintaining links with international organisations that deal with the regulation of gene technology and with agencies that regulate GMOs in countries outside Australia
- promoting the harmonisation of risk assessments relating to GMOs and GM products by regulatory agencies.

International collaboration and coordination activities undertaken during the quarter involved presentations to:

- Joint Research Centre of the European Commission workshop, ‘Comparative Situation of New Plant Breeding Techniques’, Seville, Spain, September 2011
- The Steering Group for the Environmental Considerations project of the OECD Working Group on the Harmonisation of Regulatory Oversight in Biotechnology (WGHROB), Guadalajara, Mexico, September 2011.
Advice on gene technology regulation

The Regulator and the OGTR endeavour to participate in events that inform stakeholders, the Australian community and/or users about the regulatory system.

The OGTR provided presentations to the following:

- Society for Risk Analysis Australia & New Zealand, 6th Annual Conference, Cairns, September 2011.

OGTR officers also participated in the following meetings/conferences:

- Australian Society for Microbiology, Hobart, July 2011
- International Botanical Congress, Melbourne, July 2011
- Australasian College of Toxicology and Risk Assessment 4th Annual Scientific Meeting, ‘The use of epidemiology studies in regulatory risk assessment’, Canberra, August 2011
- Sugarcane Research and Development Corporation Sugar Industry Tour, Mackay, August 2011
- ComBio 2011, Cairns, September 2011
- Asian–Pacific Weed Science Society Conference, Cairns, September 2011
- Meeting of the Gene Technology Standing Committee (GTSC), Melbourne, September 2011.

National Strategy for Unintended Presence of Unapproved GMOs

The Australian Government Biotechnology Ministerial Council has endorsed a risk-based national strategy to manage the unintended presence of unapproved GMOs in imported seeds for sowing (the UP strategy). The strategy was developed by an inter-departmental working group chaired by Biotechnology Australia and comprised of the then Department of Agriculture, Fisheries and Forestry; the Department of the Environment and Heritage; Department of Foreign Affairs and Trade; Department of Education, Science and Training; Department of Industry, Tourism and Resources; Department of Health and Ageing; FSANZ; and the OGTR.

The OGTR is responsible for implementing the UP strategy and has liaised closely with the Australian Seed Federation (ASF) to develop a voluntary auditing and testing program of existing industry quality assurance measures.

During the quarter the OGTR continued quality assurance reviews of Australian and State Government breeding programs, conducting reviews of the breeding programs of the Queensland Department of Employment, Economic Development and Innovation. No issues of concern were identified.
Guidelines
Revised Guidelines for *Certification of a Physical Containment Level 3 Invertebrate Facility, Version 2.1* were issued by the Regulator on 21 September 2011.

OGTR website usage and statistics
The OGTR website is a comprehensive source of information on activities of the office. The table below provides information on the number of hits on the OGTR website and the number of visitor sessions by month during the quarter.

<table>
<thead>
<tr>
<th>MONTH</th>
<th>HITS¹</th>
<th>VISITS²</th>
</tr>
</thead>
<tbody>
<tr>
<td>July</td>
<td>232,665</td>
<td>23,776</td>
</tr>
<tr>
<td>August</td>
<td>252,859</td>
<td>26,038</td>
</tr>
<tr>
<td>September</td>
<td>239,268</td>
<td>24,966</td>
</tr>
</tbody>
</table>

¹ ‘A hit is a request made to the server. Each file that is requested is counted as a hit
² “Visits” is the number of times the OGTR website has been visited.

The most popular pages viewed on the OGTR website during the period were:

- What's New
- Maps of Trial Sites
- List of applications and licences for Dealings involving Intentional Release (DIR) of GMOs into the environment
- Guidelines and forms for Certification of Physical Containment Facilities
- About the OGTR
- Forms and Guidelines
- Fact Sheets and Information Bulletins
- Publications
- Record of GMOs and GM Product Dealings

The most popular downloaded documents were:

- *Risk Analysis Framework*
- The Biology of *Saccharum* spp (Sugarcane)
- DIR 070/2006 Risk Assessment and Risk Management Plan
- The Biology of *Carica papaya* L. (Papaya, pawpaw, paw paw)
- The Biology of *Gossypium hirsutum* L. and *Gossypium barbadense* L. (Cotton)
• PC2 Laboratory guidelines
• The Biology of *Ananas comosus* var. *comosus* (Pineapple)
• The Biology of Hybrid Tea Rose (*Rosa x hybrida*)
• DIR 066/2006 Risk Assessment and Risk Management Plan

The OGTR welcomes feedback on ways to improve the provision of information on gene technology regulation.

**Internet contacts and freecall number**

**OGTR email address and freecall number**

The OGTR’s 1800 number and email address are points of contact for members of the public and other interested parties to obtain information about the regulation of GMOs. Assistance with specific questions and additional mechanisms for public feedback are among some of the services provided by the 1800 line and email facilities. The table below describes the activity of these facilities throughout the quarter.

<table>
<thead>
<tr>
<th>MONTH</th>
<th>EMAILS</th>
<th>OGTR 1800 NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>July</td>
<td>65</td>
<td>98</td>
</tr>
<tr>
<td>August</td>
<td>108</td>
<td>123</td>
</tr>
<tr>
<td>September</td>
<td>104</td>
<td>102</td>
</tr>
</tbody>
</table>

**Monitoring and compliance email inbox**

The OGTR maintains an email inbox to provide a central point for accredited organisations to contact the OGTR regarding monitoring and compliance matters, such as queries, notifications required under licences, and self reporting of non-compliances. The email inbox ensures that all communications are answered efficiently while monitoring staff are away from the office. The inbox received 142 emails during the quarter.

**Statutory Committee email inbox**

The Regulatory Practice and Secretariat Section maintain an email inbox to facilitate efficient communication between committee members and secretariat staff.

The inbox ensures that all communications are answered in a timely manner by secretariat staff. The inbox received 321 emails during the quarter.
Application and Licence Management email inbox
This electronic mail inbox provides a central, shared communication point to allow efficient coordination of responses for correspondence and queries about applications received by the Application and Licence Management Section. The inbox received 691 emails during the quarter.

Contained Dealings Evaluation Section email inbox
This email inbox provides a central common point for efficient coordination of responses to queries relating to classification of GMO dealings, certification requirements for higher level containment facilities and GMO licences accessed by the contained dealings evaluation section. The inbox received 149 emails during the quarter.
## GLOSSARY

This section contains a brief description of terms relevant to an understanding of this quarterly report. They do not substitute for definitions of terms relevant to the operation of the gene technology regulatory system that are contained in section 10 of the *Gene Technology Act 2000*.

<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accredited organisation</td>
<td>An organisation that is accredited under section 92 of the Act</td>
</tr>
<tr>
<td>Act</td>
<td><em>Gene Technology Act 2000</em></td>
</tr>
<tr>
<td>APVMA</td>
<td>Australian Pesticides and Veterinary Medicines Authority</td>
</tr>
<tr>
<td>BSG</td>
<td>Biosecurity Services Group of the Department of Agriculture, Fisheries and Forestry</td>
</tr>
<tr>
<td>Breach of a licence condition</td>
<td>A breach of a licence condition which has been proven either in court or by way of admission following investigation</td>
</tr>
<tr>
<td>CCI</td>
<td>Confidential commercial information</td>
</tr>
<tr>
<td>Certified containment facility</td>
<td>A building or place certified by the Regulator to a specified containment level under section 84 of the Act</td>
</tr>
<tr>
<td>Clock stop</td>
<td>The period during which time does not run for purposes of the statutory time limit for making a decision—usually because evaluation cannot proceed until additional information requested from the applicant is received</td>
</tr>
<tr>
<td>CSIRO</td>
<td>Commonwealth Scientific and Industrial Research Organisation</td>
</tr>
<tr>
<td>DIR</td>
<td>A dealing involving intentional release of a GMO into the environment (e.g. field trial or commercial release)</td>
</tr>
<tr>
<td>DIR licence</td>
<td>A licence for a dealing involving intentional release of a GMO into the environment</td>
</tr>
<tr>
<td>DNIR</td>
<td>A contained dealing with a GMO not involving intentional release of the GMO into the environment (e.g. experiments in a certified facility such as a laboratory)</td>
</tr>
<tr>
<td>DNIR licence</td>
<td>A licence for a dealing not involving intentional release of a GMO into the environment</td>
</tr>
<tr>
<td>Expert advisers</td>
<td>Advisers appointed by the Minister to give expert advice to either GTTAC or GTECCC to assist them in the performance of their functions (expert advisers are not committee members)</td>
</tr>
<tr>
<td>EDD</td>
<td>Emergency dealing determination</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>FSANZ</td>
<td>Food Standards Australia New Zealand</td>
</tr>
<tr>
<td>GM</td>
<td>Genetically modified</td>
</tr>
<tr>
<td>GM product</td>
<td>A thing (other than a GMO) derived or produced from a GMO</td>
</tr>
<tr>
<td>GMAC</td>
<td>Genetic Manipulation Advisory Committee</td>
</tr>
<tr>
<td>GMO</td>
<td>Genetically modified organism</td>
</tr>
<tr>
<td>GTECCC</td>
<td>Gene Technology Ethics and Community Consultative Committee</td>
</tr>
<tr>
<td>GTMC</td>
<td>Gene Technology Ministerial Council</td>
</tr>
<tr>
<td>GTSC</td>
<td>Gene Technology Standing Committee</td>
</tr>
<tr>
<td>GTTAC</td>
<td>Gene Technology Technical Advisory Committee</td>
</tr>
<tr>
<td>IBC</td>
<td>Institutional Biosafety Committee</td>
</tr>
<tr>
<td>Incident</td>
<td>A self-reported event which may constitute a non-compliance with regulatory requirements and a public health or environment risk</td>
</tr>
<tr>
<td>Limited and controlled release</td>
<td>A type of DIR which meets certain criteria relating to limiting and controlling the dealings with the GMO (e.g. a field trial)</td>
</tr>
<tr>
<td>NLRD</td>
<td>Notifiable low risk dealing (work with transgenic plants, animals or microorganisms undertaken in certified contained facilities)</td>
</tr>
<tr>
<td>Non-compliance</td>
<td>An inconsistency between an event or state of affairs and the requirements imposed by licence accreditation or certification conditions, or any of the requirements of the Act or Regulations</td>
</tr>
<tr>
<td>OGTR</td>
<td>Office of the Gene Technology Regulator</td>
</tr>
<tr>
<td>PC1, PC2, PC3, PC4</td>
<td>Physical containment levels of facilities as certified by the Regulator</td>
</tr>
<tr>
<td>RARMP</td>
<td>Risk assessment and risk management plan</td>
</tr>
<tr>
<td>Regulations</td>
<td>Gene Technology Regulations 2001</td>
</tr>
<tr>
<td>Regulator</td>
<td>Gene Technology Regulator</td>
</tr>
<tr>
<td>Spot checks</td>
<td>Unannounced visits by the OGTR Monitoring and Compliance Section</td>
</tr>
<tr>
<td>Volunteer</td>
<td>Regrowth of plants from seed that has remained on a site after a trial has been completed</td>
</tr>
</tbody>
</table>